{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-24-000034","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.461043+00:00","generated_at":"2026-06-02T02:39:07.384725+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Barinthus Bio Q1 net loss $15.5M ($0.40/sh); cash $130M; VTP-1000 IND cleared for celiac trial","bullets":["Net loss attributable to shareholders of $15.5M vs $18.2M in Q1 2023; revenue nil (vs $0.5M).","Cash, cash equivalents and restricted cash of $130.0M as of March 31, 2024; cash runway into Q4 2025.","R&D expenses $11.1M (up from $9.8M), G&A $6.0M (down from $12.1M).","FDA IND clearance received for VTP-1000 Phase 1 trial in celiac disease; first patient dosing expected Q3 2024.","Appointed Dr. Leon Hooftman as CMO, effective June 3, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-24-000034","json":"https://secwatch.observer/filing/0001828185-24-000034.json","markdown":"https://secwatch.observer/filing/0001828185-24-000034.md","text":"https://secwatch.observer/filing/0001828185-24-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000034/0001828185-24-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000034/brns-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:39:07.384725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5c1a256c34f4461edf26a5adc5f2909290b801e","claim":"Barinthus Biotherapeutics plc. reported financial results for first quarter of 2024.","evidence_excerpt":"On May 13, 2024, Barinthus Biotherapeutics plc (the “Company”) announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress. The full text of the press release issued in connection with the update is furnished as Exhibit 99.1 to this Current Report on Form 8-K.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000034/0001828185-24-000034-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}